Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlycoVaxyn, a developer of conjugated vaccines, has closed a $22 million series B financing.
Subscribe to our email newsletter
The round was led by Edmond de Rothschild Investment Partners. Existing investors, Index Ventures and Sofinnova Partners, expressed their commitment to the future of the company through significant participation in this round.
The new funds will be used to advance the company’s lead vaccine candidate for intestinal infections (shigellosis), which can cause a major public health issue, into clinical development within the next 12 months. GlycoVaxyn also aims to reach key milestones in its Staphylococcus aureus, Group B meningococcal and Group A Streptococcus conjugate vaccine programs.
In conjunction with the financing, Gilles Nobecourt, partner at Edmond de Rothschild Investment Partners, has joined GlycoVaxyn’s board of directors.
Michel Greco, chairman of GlycoVaxyn, said: “Under the leadership of CEO Philippe Dro, GlycoVaxyn has established the solid fundamentals required to raise funding in the current economic downturn. The company is well financed for the move into clinical trials and as the team continues to deliver on its business strategy, we look forward to the additional support from our new board member, Gilles.”